Physician profile
John M Roach
NPI 1518921766
$3,578.59
in general payments reported to CMS, 2019-2025
20 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $348 · 2021: $420 · 2022: $258 · 2023: $409 · 2024: $1,207 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,546 · Long Term Medical Supply Or Device Loan: $560 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.94 |
| Long Term Medical Supply Or Device Loan | $560.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $560.00 | 2024 | Dextenza |
| Alcon Vision LLC | $547.86 | 2020-2025 | Hydrus Microstent, Voyager Dslt, Rocklatan |
| Allergan, INC. | $520.72 | 2019-2022 | |
| Abbvie INC. | $397.36 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Glaukos Corporation | $227.70 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $215.82 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $153.49 | 2020-2023 | |
| Harrow Eye, LLC | $129.82 | 2024-2025 | Vevye, Iheezo |
| Alimera Sciences, INC. | $127.49 | 2019 | |
| Oyster Point Pharma, INC. | $120.95 | 2022-2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $106.04 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Veritas Vision System |
| Ivantis, INC | $99.24 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $87.93 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $74.47 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $63.80 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.50 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.40 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $37.75 | 2021 | |
| Merck Sharp & Dohme LLC | $14.42 | 2025 | Bridion |
| Sight Sciences, INC. | $11.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.